Suzhou Biomissile Pharmaceuticals Co., Ltd.

This is the first study in humans testing a new drug called BM230 for people with advanced solid tumors that have a specific marker called HER2. The main goal is to find a safe dose and see how the body handles the drug. It's for patients whose cancer has continued to grow despit…